Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2017 June;61(2) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2017 June;61(2):153-67

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW  NEW TRACERS TO THE CLINIC: TRANSLATIONAL STUDIES 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2017 June;61(2):153-67

DOI: 10.23736/S1824-4785.17.02971-5

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Radiolabeled peptides: current and new perspectives

Marta OPALINSKA, Alicja HUBALEWSKA-DYDEJCZYK, Anna SOWA-STASZCZAK

Department of Endocrinology, Jagiellonian University, Medical College, Krakow, Poland


PDF


Radiolabeled peptides have been the subject of research for over 20 years and during that time possibility/variety of peptide receptor imaging and later targeted radiotherapy increased significantly. The targeted receptors belong to the large family of G-protein-coupled receptors or tyrosine kinases receptors partially connected with them. They both regulate large signaling networks, control multiple cell functions and are implicated in many diseases including cancers. The essential feature of peptides used in nuclear medicine involves their ability to binding with high affinity and specify to their receptors overexpressed on tumor cells. Currently most important peptide radiotracers are somatostatin, GLP-1, bombesin, gastrin/cholecystokinin-2, neurokinin type 1, CXCR4, EGF, VEGF and integrins. These tracers are mainly based on nuclides which are radiometals or on 18F and may be used in both SPECT or PET techniques as well as for hybrid imaging. Using of chelators suitable for peptide labeling with diagnostic and therapeutic radionuclids enables the theranostic approach. In this review we will provide a brief overview over currently available radiopharmaceuticals based on different groups of peptides.


KEY WORDS: Neuroendocrine tumors - Radiotherapy - Peptides

top of page